BEDMINSTER, N.J., 3. Juni 2022 — Jubilant Therapeutics Inc., ein Unternehmen für Präzisionstherapeutika in der klinischen Phase, das niedermolekulare Therapeutika für ungedeckten medizinischen Bedarf in der Onkologie und bei Autoimmunerkrankungen …
Topic:
asco
-
-
Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting
by Your NewsThese data are part of a New Drug Application that has been granted priority review by the U.S. Food and Drug Administration PRINCETON, N.J., June 3, 2022 — Taiho Oncology, …